it was developed by eisai co and acts as a multiple kinase inhibitor against the vegfr1 vegfr2 and vegfr3 kinases lenvatinib is approved since 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent or metastatic progressive and did not respond to treatment with radioactive iodine radioiodine in may 2016 the us fda approved it in combination with everolimus for the treatment of advanced renal cell carcinoma following one prior anti angiogenic therapy hypertension high blood pressure was the most common side effect in studies 73 of patients versus 16 in the placebo group followed by diarrhoea 67 vs 17 and fatigue 67 vs 35 other common side effects included decreased appetite hypotension low blood pressure thrombocytopenia low blood platelet count nausea muscle and bone pain as lenvatinib moderately prolongs qt time addition of other drugs with this property could increase the risk of a type of abnormal heart rhythm namely torsades de pointes no relevant interactions with enzyme inhibitors and inducers are expected lenvatinib acts as a multiple kinase inhibitor it inhibits the three main vascular endothelial growth factor receptors vegfr1 2 and 3 as well as fibroblast growth factor receptors fgfr 1 2 3 and